---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-096025"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:15.543924+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed announces 1-for-20 reverse share split to regain Nasdaq $1 bid compliance

## Summary
- Consolidation ratio 1:20 reduces shares from ~14.36M to ~718k on a non-diluted basis.
- Effective with Nasdaq on Nov 14, 2024; adjusted trading begins Nov 15, symbol INM unchanged.
- No fractional shares issued; fractions under 0.5 cancelled, otherwise rounded up.
- Proportionate adjustment to exercise prices and share counts of options/warrants/convertibles.
- Action taken to meet Nasdaq minimum $1.00 bid price continued listing requirement.

## SEC filing metadata
- accession: 0001213900-24-096025
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024096025/0001213900-24-096025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024096025/ea0220578-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-096025
- JSON: https://secwatch.observer/filing/0001213900-24-096025.json
- Plain text: https://secwatch.observer/filing/0001213900-24-096025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.